Ask AI
ARIA Training Module

CE / CME

Spot the Signal: Global Radiology Training for ARIA Detection in Alzheimer’s Care

Physician Assistants/Physician Associates: 1.00 AAPA Category 1 CME credit

Physicians: Maximum of 1.00 AMA PRA Category 1 Credit

European Learners: 1.00 EBAC® CE Credit

Released: April 16, 2026

Expiration: April 15, 2027

Activity

Progress
1 2 3
Course Completed

Case 1: ARIA-H Management

Dr Benzinger:

This case was mild ARIA-H, so clinical management (the decision to suspend dosing) will depend upon whether this patient is having symptoms.

Management decisions depend on both radiologic severity and clinical symptoms. Options include continued treatment with closer monitoring, temporary suspension of therapy until findings resolve or stabilize, dose adjustment, or permanent discontinuation.3,4 Radiologists should clearly report the ARIA grade and recommend follow-up MRI, recognizing that treating HCPs may choose a more conservative approach than the minimum required by the product labeling.

Case 1: ARIA-E Management

Dr Benzinger:

Radiology would definitely recommend that the patient get a follow-up MRI to make sure that the ARIA-E resolves over time, which we would expect. We also expect that those hemorrhages should stabilize, and we should not see new ones. If new hemorrhages appear, we need to continue monitoring with MRI more frequently than the normally indicated schedule.

Case 1: Summary and Key Takeaways

Dr Benzinger:

This case has several take-home messages.

This patient did have 1 APOE4 allele, so we know from the outset that they have a higher risk for ARIA than the general population.

This case provides a great example of how scoring systems may not align with a radiologist’s intuitive sense of lesion severity. It further emphasizes the importance of applying standardized grading systems since the identification and grading by the radiologist drives clinical management.

In addition, radiology should be vocal in recommending follow-up scans even when therapy is paused because patients are still at risk for progression even if they don’t continue to receive the ATT.

In this case, the patient was asymptomatic, but the clinical team decided to hold the infusion because of the involvement of 2 separate areas, both of which included hemorrhages. This illustrates that management may be individualized and more cautious than labeling alone might suggest.